In our previous study (18) we followed 48 chronic hepatitis C (CHC) patients who were either partial responders PR (ALT between 30–80 IU/l); or non-responders: NR (ALT >80 IU/l, longer than 6 months) to initial IFN therapy, and were given anti-inflammatory drugs (19) such as Stronger Neo-Minophagen (SNMC), Ursodeoxy-cholic acid (UDCA) and Shosaioko-to, to subside inflammation and suppress ALT activity. This evidence concerns the gene GPT and chronic hepatitis C virus infection.